Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?
Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
SIBN - SI-BONE, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$23.00
DETAILS
HIGH:
$25.00
LOW:
$21.00
MEDIAN:
$23.00
CONSENSUS:
$23.00
UPSIDE:
19.79%
Stock News
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade
The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?
The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SiBone Q2 Earnings Call Highlights
SiBone (NASDAQ: SIBN) reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio. Worldwide revenue reached $56 million for the quarter ended June 30, while U.S. revenue increased 14.7% to $53.2 million. International revenue grew 25.9% to
SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.14 per share a year ago.
SiBone Q2 Earnings Call Highlights
SiBone NASDAQ: SIBN reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio.
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
Delivered ~15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base
SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026
SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board Member Appointments build the financial and governance foundation for ViCentra's next phase, following the recent scale-up of commercial manufacturing UTRECHT, The Netherlands, July 14, 2026 (GLOBE NEWSWIRE) -- ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced the appointment of Ian Wells as Chief Financial Officer, effective June 19, 2026, and the addition of Thomas A. West, a veteran U.S. medical technology leader, to its Board of Directors as an Independent Director, effective July 1, 2026.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time.
Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now
Si-Bone (SIBN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 71.1% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Gazprom Neft says Q1 profit down 3.5% y/y
Gazprom Neft , the oil arm of Russia's energy giant Gazprom , said on Friday its first-quarter net profit declined by 3.5% year-on-year to 95.8 billion roubles ($1.35 billion).
How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%
The consensus price target hints at a 65.3% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
SiBone Q1 Earnings Call Highlights
SiBone NASDAQ: SIBN raised its full-year 2026 outlook after reporting double-digit revenue growth in the first quarter, with management pointing to new product launches, expanding physician adoption, international momentum and a proposed Medicare reimbursement change as key drivers for the year ahead.
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA
Price Targets
SI-Bone price target raised to $25 from $24 at UBS
$25.00
(was $18.65)
Patrick Wood
·
UBS
SI-Bone initiated with a Buy at UBS
$24.00
(was $17.05)
Patrick Wood
·
UBS
SI-Bone price target raised to $21 from $18 at Truist
$21.00
(was $17.92)
Truist Financial
SI-Bone price target raised to $24 from $23 at Truist
$24.00
(was $15.62)
Truist Financial
SI-Bone price target raised to $23 from $21 at Truist
$23.00
(was $19.62)
Truist Financial
SI-Bone price target raised to $27 from $26 at Canaccord
$27.00
(was $19.42)
William Plovanic
·
Canaccord Genuity
SI-BONE Inc. (SIBN) PT Raised to $27 at Needham, Added To Conviction List
$27.00
(was $19.16)
David Saxon
·
Needham
SI-Bone price target raised to $23 from $20 at Morgan Stanley
$23.00
(was $18.87)
Morgan Stanley
SI-Bone price target lowered to $20 from $22 at Truist
$20.00
(was $15.27)
Richard Newitter
·
Truist Financial
Cantor Fitzgerald Reiterates Overweight Rating on SI-BONE Inc. (SIBN)
$25.00
(was $15.68)
Ross Osborn
·
Cantor Fitzgerald
SI-Bone price target lowered to $18 from $20 at Truist
$18.00
(was $14.04)
Samuel Brodovsky
·
Truist Financial
SI-BONE Inc. (SIBN) PT Lowered to $19 at Needham
$19.00
(was $14.36)
David Saxon
·
Needham
SI-Bone initiated with an Overweight at Piper Sandler
$25.00
(was $15.82)
Matt O'Brien
·
Piper Sandler
SI-BONE Poised For A Surge: Analyst Highlights Upside Potential With New Product Launches
$32.00
(was $26.93)
David Saxon
·
Needham
Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $18
$18.00
(was $12.58)
Morgan Stanley
Truist Securities Maintains Buy on SI-BONE, Lowers Price Target to $17
$17.00
(was $11.77)
Truist Financial
Morgan Stanly Says These 3 Stocks Could Surge Over 60% From Current Levels
$22.00
(was $12.50)
Drew Ranieri
·
Morgan Stanley